Sanofi ADS (SNY)
FairStock Score: 56/100 — STEADY
Key Financials
| Current Price | $41.6 |
| Market Cap | $114.2B |
| P/E Ratio | 22.49 |
| ROE | 5.71% |
| Dividend Yield | 5.7% |
| Sector | Healthcare |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Sanofi is a large healthcare company selling vaccines and medicines for immunology, rare disease, neurology and oncology. The business has durable demand and scale, but the numbers in front of me are mixed. In the second quarter of fiscal 2026, revenue was $12.3B, but net income was only $343.0M, a 2.79% margin. That is thin for a drugmaker. FairStock's returns are modest: ROE 5.71% and ROCE 5.09%. A company with a strong moat should earn better on capital. The balance sheet looks reasonable with D/E 0.34, and trailing free cash flow is $7.0B, a 6.1% FCF yield. The dividend yield is 5.70%, and beta is 0.28, so the stock has been defensive. At the 2026-10-13 close of $39.12, FairStock's P/E is 21.15 and P/B is 1.16. Its Graham Number is $48.71, giving a 19.69% margin of safety. The Piotroski F-Score is 5/9 and Altman Z-Score is 1.30, which suggests middling financial momentum and some balance-sheet risk. The price is near the bottom of the 52-week range of $39.07–$52.68. I see a cheap-looking valuation against assets and cash flow, but weak profitability and no assigned Lynch category—FairStock says only 0 years of filed results, needing 3—keep me cautious. I would want evidence that margins and returns on capital are recovering before calling this a high-quality bargain.
In plain English: Sanofi makes vaccines and medicines for immune diseases, rare diseases, neurology and cancer. The business looks mixed: sales are large, but the latest quarter's profit was very thin, and the company is not earning much on the money it invests. The shares sit near their lowest price of the past year and pay a high dividend, so they look inexpensive to fair, but not clearly cheap while profits are weak.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash
Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer